GFAP and myeloid sarcoma: Although the small sample size of our MS patients and control cohorts represents a limitation for the interpretation of the biomarker expression, we observed a reduction of median serum GFAP levels under siponimod treatment, hinting at a potential beneficial effect on astrocyte-mediated pathomechanisms of progression besides the reduced CNS immune cell infiltration.